Jack Penney

Massachusetts General Hospital, Boston, MA 
basal ganglia, Parkinson's disease, Huntington's disease
"Jack Penney"
Mean distance: 15.51 (cluster 32)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Biglan KM, Shoulson I, et al. (2015) Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. Jama Neurology. 1-9
Brocklebank D, Gayán J, Andresen JM, et al. (2009) Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 150: 425-9
Andresen JM, Gayán J, Djoussé L, et al. (2007) The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Annals of Human Genetics. 71: 295-301
Li JL, Hayden MR, Warby SC, et al. (2006) Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. Bmc Medical Genetics. 7: 71
Hogarth P, Kayson E, Kieburtz K, et al. (2005) Interrater agreement in the assessment of motor manifestations of Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 293-7
Deng YP, Albin RL, Penney JB, et al. (2004) Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. Journal of Chemical Neuroanatomy. 27: 143-64
Wexler NS, Lorimer J, Porter J, et al. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proceedings of the National Academy of Sciences of the United States of America. 101: 3498-503
Wheelock VL, Tempkin T, Marder K, et al. (2003) Predictors of nursing home placement in Huntington disease. Neurology. 60: 998-1001
Spektor BS, Miller DW, Hollingsworth ZR, et al. (2002) Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Research. Molecular Brain Research. 102: 118-28
Shoulson I, Oakes D, Fahn S, et al. (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology. 51: 604-12
See more...